What is NPCE's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.43B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for NPCE?

P/E (TTM) is n/a and 52-week range is $9.22 to $19.60 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s NPCE figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for NPCE?

The company profile lists revenue (TTM) near $99M, net income (TTM) near $-1.91B, EPS (TTM) near $-0.57 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Neuropace Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Mountain View, California, US, 34.1M shares outstanding, ISIN US6412881053 when available from company profile and filing metadata.

Neuropace Inc

$NPCE

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$12.67

+2.26%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California and currently employs 209 full-time employees. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The firm has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.

Employees

209

Website

www.neuropace.com/

IPO

2021-04-22

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)